Wells Fargo & Company MN increased its position in Protagonist Therapeutics Inc (NASDAQ:PTGX) by 60.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,565 shares of the company’s stock after acquiring an additional 3,617 shares during the quarter. Wells Fargo & Company MN’s holdings in Protagonist Therapeutics were worth $169,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Rhumbline Advisers bought a new position in shares of Protagonist Therapeutics in the second quarter valued at approximately $114,000. Teachers Advisors LLC boosted its position in shares of Protagonist Therapeutics by 71.4% in the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after acquiring an additional 6,757 shares during the period. California State Teachers Retirement System boosted its position in shares of Protagonist Therapeutics by 8.5% in the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after acquiring an additional 1,300 shares during the period. First Manhattan Co. bought a new position in shares of Protagonist Therapeutics in the third quarter valued at approximately $293,000. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Protagonist Therapeutics by 19.5% in the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock valued at $264,000 after acquiring an additional 3,812 shares during the period. Institutional investors own 42.35% of the company’s stock.

In other Protagonist Therapeutics news, CFO Thomas P. O’neil sold 8,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $20.00, for a total transaction of $160,000.00. Following the completion of the sale, the chief financial officer now directly owns 4,000 shares in the company, valued at $80,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $16.97, for a total transaction of $118,790.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,944 shares of company stock valued at $438,629. 15.50% of the stock is currently owned by company insiders.

PTGX has been the subject of a number of analyst reports. BMO Capital Markets cut their price objective on shares of Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, October 19th. Zacks Investment Research lowered shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 18th. BidaskClub upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Finally, Stifel Nicolaus initiated coverage on shares of Protagonist Therapeutics in a research report on Monday, January 29th. They issued a “buy” rating and a $32.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $32.50.

Shares of Protagonist Therapeutics Inc (NASDAQ PTGX) opened at $17.03 on Friday. Protagonist Therapeutics Inc has a 1 year low of $8.00 and a 1 year high of $23.75.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Monday, November 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.40. The company had revenue of $8.78 million for the quarter. sell-side analysts expect that Protagonist Therapeutics Inc will post -2.32 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/02/09/wells-fargo-company-mn-has-169000-stake-in-protagonist-therapeutics-inc-ptgx.html.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.